Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that members of its management and business development team will attend the 10th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, known as MSToronto2026, being held October 21–23, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. The joint ACTRIMS-ECTRIMS meeting is a premier international scientific forum uniting researchers, clinicians, and industry leaders focused on advances in multiple sclerosis (MS) and related neuroinflammatory disorders.